Behavioural Neuroscientific Systems and the Bronowski Institute of Behavioural Neuroscience are solving one of the largest health related problems of global culture. We have created a medical device for treating depression, insomnia and fatigue and this is especially effective in treating the symptoms of Parkinson's disease. This device has been conceived and tested and developed in manual form since 1996 and we are now moving ahead to develop the device in electronic form.
We envisage 2 stages of development: Stage one of our device, will be on the global market within 18 months. The second stage will be completed within 6 to 12 months after the first. This strategy will capture a large proportion of the market, especially when good marketing people, draw on the major advances we have made, with support from professional bodies and the general public. The novel and inventive I.P. has been protected with a patent filed in August this year and will provide a high barrier to entry of the competition. The first is the clinical/scientific team lead by myself, Greg Willis, since the project commenced. Several supporting staff and students have contributed since 1996 with 2 or 3 key associations. Mrs Jane Holth, president of the Bronowski Institute holds a key role in the liaison of BNS with our important scientific collaborators. Our professional affiliation with Dr. Sakoda and Dr Endo at Toneyama National hospital (Osaka) serves as an effective liaison for Japan in approaching the global market. Dr Alan Robertson, is an advisory board member (ex. Pharmaxis) and Mr Jeffrey Mariner serves as our R&D commercial advisor. Dr David Menzies of Outerspace Pty Ltd is working on finalising the electronic version.
We have traction in demonstrating that our device is based on effective clinical use over 25 years which has gained support from medical professionals and the general public. We have treated patients here in Australia, the U.S., Europe with a large following in Japan: already this is a growing client base. With the intention of registering the device with regulatory bodies, our exiting professional acceptance in the U.S. (see Center for Environmental Therapeutics.org) and our long standing affiliation with Japan, plus our following in Australia provides a rapidly expanding client base. Investment in this project to date has been from internal sources and is $A3.9M.
Ready to Ask For Funding for your company?
Post a Funding Request